Research

hand-281963_640

Cannabinoid, Dronabinol, Seen as Long-term Treatment Option for Neuropathic Pain in Phase 3 Study

Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients being treated with dronabinol, a cannabinoid, do not show signs of drug abuse or dependency, leading researchers to conclude it has potential to be a long-term and safe treatment option for neuropathic pain.

Cannabinoid, Dronabinol, Seen as Long-term Treatment Option for Neuropathic Pain in Phase 3 Study Read More »

result-2153527_640

Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports

Source Multiple Sclerosis News Today: Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated with ozanimod had lower relapse rates and fewer MRI brain lesions compared to those given a current first-line therapy, Avonex (interferon β-1a). These results will be used to support a request for ozanimod’s approval as an MS therapy

Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports Read More »

Scroll to Top